Donor cell therapy for relapsed or refractory multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new type of cell therapy made from donor cells, called CAR-NK cells. The cells are designed to find and attack myeloma cells. The goal is to see if this treatment can help people whose myeloma has not responded to multiple prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old
- You need to have tried at least three prior treatments for multiple myeloma (including certain types), and it must still be active
- Your cancer should be measurable, like a certain level of protein in blood or urine
- You should be in generally good health, with adequate blood counts, kidney and liver function
- You cannot have serious heart, lung, or active infection problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called CAR-T cell therapy for people with multiple myeloma that has come back or not responded to other treatments. The treatment uses your own immune cells, modified in a lab to attack the cancer, and may be an option after a stem cell transplant has not worked.
This trial tests a new treatment called CAR-T cell therapy that uses your own immune cells to fight cancer. It is for people with multiple myeloma or plasma cell leukemia that has come back or not responded to other treatments.
This trial tests a special type of immune therapy called CAR T cells, which are made from your own blood cells and then given back to you to fight the cancer. It is for people with multiple myeloma who have not gotten better with other treatments or whose cancer has come back.
This trial tests a new type of treatment using your own immune cells (called CAR-T cells) that target two proteins on myeloma cells: BCMA and GPRC5D. It's for people whose myeloma has come back or stopped responding to standard treatments, and who may have few other options left.
This Phase 1/2 study tests a personalized CAR-T cell treatment that targets a protein called BCMA on myeloma cells. It’s designed for people with multiple myeloma who have already tried several other treatments and still have measurable disease.
This study tests a new type of cell therapy called BCMA-GPRC5D CAR-T for people whose multiple myeloma has come back or not responded to standard treatments. The therapy uses your own immune cells, modified in a lab, to find and attack myeloma cells.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.